Shaping the future of cancer treatment with powerful therapeutic and diagnostic platforms
Novel cancer immunotherapies combining Affimer® biotherapeutics and pre|CISION™ tumour activated chemotherapy
Affimer-based rapid point of care, laboratory and research ELISA tests for COVID-19 coronavirus infection
Rapid development of high performance Affimer® immunoassays for diagnostics and clinical trial support
Diagnostics
Affimer® reagents are ideal tools for use in a wide variety of diagnostic applications.
Investors
Significant long-term value, growing a pipeline of drug candidates
A proven platform technology able to address multiple markets, with significant potential as the Group builds a pipeline of valuable drug assets for development and licensing.
Featured news
Launch of SARS-CoV-2 BAMSTM Research Test
Latest news